Example: biology
DS-7300 Seminar
DS-7300 Mechanism of Action DS-7300 is an antibody-drug conjugate (ADC) composed of a humanized anti–B7- H3 immunoglobulin G1 (IgG1) monoclonal antibody …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Daiichi Sankyo Group Value Report 2020
www.daiichisankyo.com5-year business plan period was the launch of ENHERTU (generic name: trastuzumab deruxtecan; project code number: DS-8201) in the U.S. and Japan in 2020, and the start of contribution to patients. The product is indicated for the 3rd-line treatment of HER2 positive breast cancer. For ENHERTU, we formed a strategic collaboration
FINAL - DS-7300 ESMO Data Press Release 09162021
www.daiichisankyo.comSep 17, 2021 · B7-H3 is frequently overexpressed in a wide range of cancers including lung, prostate, breast, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma, and its overexpression is associated with poor prognosis.1,2,3 No B7-H3 directed therapies are currently approved for treatment of any cancer.
Press Release
www.daiichisankyo.comDec 23, 2021 · Metastatic Breast Cancer In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).
Press Release - Daiichi Sankyo
www.daiichisankyo.comJun 11, 2021 · Treatment of Patients with Malignant Glioma • First oncolytic virus ever approved for treatment of malignant glioma or any primary brain cancer • Fourth innovative oncology medicine approved in Japan over the past two years for Daiichi Sankyo Tokyo – (June 11, 2021) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today
Consolidated Financial Results for the First Nine Months ...
www.daiichisankyo.comFeb 04, 2022 · Note: Regarding the forecast of consolidated financial results for the fiscal year ending March 31, 2022, Daiichi Sankyo discloses core operating profit, which excludes t emporary income and expenses from operating profit, as an indicator of ordinary profitability. For the definition of core operating profit, please refer to “1.
Press Release
www.daiichisankyo.comFeb 21, 2022 · About Breast Cancer and HER2 Expression Breast cancer is the most common cancer and is one of the leading causes of cancer-related deaths worldwide.7 More than two million cases of breast cancer were diagnosed in 2020 …
Related documents
DRUG NAME: Trastuzumab
www.bccancer.bc.caCLASSIFICATION: molecular targeted therapy . Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Trastuzumab is a human monoclonal IgG antibody which selectively targets HER2, a human epidermal growth factor receptor (EGFR).
がんのバイオマーカー - Pmda
www.pmda.go.jpTrastuzumab Emtansine ERBB2 (HER2) Indications and Usage, Warnings and Precautions, Adverse Reactions, ... matched therapy: changes from baseline in tumor measurements (waterfall plot). ... An example of an integrative approach to pathway analysis of a drug-sensitive versus drug-resistant population of patients. Nat. Rev. Clin. Oncol.
DRUG NAME: Trastuzumab emtansine
www.bccancer.bc.caMECHANISM OF ACTION: Trastuzumab emtansine is an antibody -drug conjugate incorporating the monoclonal antibody trastuzumab and emtansine. The emtansine moiety is comprised of two components, DM1, a microtubule inhibitor, and MCC, a thioether linker. Trastuzumab emtansine binds to human epidermal growth factor 2 (HER2) receptors and …
SCIENTIFIC DISCUSSION 1. Introduction
www.ema.europa.euTrastuzumab is formulated as a lyophilised powder and each vial is designed to deliver 150 mg trastuzumab. The finished product also includes 3.36 mg L-Histidine HCl, 2.16 mg L-Histidine, 136.2 mg trehalose, dihydrate, and 0.6 mg polysorbate 20. The sterile solution is filled aseptically into 15 ml Type I borosilicate glass vials with 20 mm
Guidelines for the Management of Extravasation of a ...
www.england.nhs.ukMgt of Extravasation of a Systemic Anti-Cancer Therapy including Cytotoxic Agents v1.docx Document Purpose The purpose of this guideline is to provide clear guidance on the causes, prevention, recognition and management of an extravasation of a Systemic Anti-Cancer Therapy used in the treatment of malignant disease in the patient